|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aligos Therapeutics, Inc. (ALGS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
72,010,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aligos Therapeutics is a clinical-stage biopharmaceutical company. Co. utilizes its proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Co. has developed a portfolio of differentiated drug candidates for Chronic Hepatitis B, including a small molecule Capsid Assembly Modulator and oligonucleotides, each of which is designed against clinically validated targets in the Hepatitis B Virus life cycle. Co. is also exploring approaches towards boosting immune response with the use of small molecule antagonists of the PD1/PD-L1 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
7,933,601 |
7,933,601 |
| Total Buy Value |
$0 |
$0 |
$6,004,149 |
$6,004,149 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roche Finance Ltd |
10% Owner |
– – • |
2023-10-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
11,025,941 |
|
- |
|
| Blatt Lawrence |
Chief Executive Officer |
• • – |
2023-10-25 |
4 |
A |
$0.76 |
$461,858 |
D/D |
610,277 |
1,847,575 |
|
- |
|
| Scopa James Paul |
|
• • – |
2023-10-25 |
4 |
A |
$0.76 |
$138,557 |
D/D |
183,083 |
183,083 |
|
- |
|
| Nuechterlein Carole |
|
• • • |
2023-10-25 |
4 |
B |
$0.76 |
$6,004,149 |
I/I |
7,933,601 |
11,025,941 |
0.01 |
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,226 |
4,452 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-06-11 |
4 |
AS |
$0.00 |
$0 |
I/I |
(504,081) |
0 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
I/I |
18,102 |
8,383 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,226 |
2,226 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-04-26 |
4 |
AS |
$0.00 |
$0 |
I/I |
(504,084) |
0 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
18,105 |
8,385 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,906,191 |
1,906,191 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2020-10-20 |
4 |
B |
$15.00 |
$3,000,000 |
D/D |
200,000 |
2,614,563 |
2.45 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,414,563 |
2,414,563 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2020-10-20 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
862,444 |
2.1 |
- |
|
| Woiwode Thomas |
Director |
– • – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
3,092,339 |
662,444 |
|
- |
|
| Quan Lucinda Y. |
See Remarks |
• – – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
9,258 |
9,258 |
|
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2020-10-20 |
4 |
B |
$15.00 |
$8,250,000 |
I/I |
550,000 |
430,372 |
1.5 |
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
2,997,030 |
363,639 |
|
- |
|
| Versant Vantage I, L.p. |
10% Owner |
– – • |
2020-10-20 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
862,444 |
1.5 |
- |
|
| Versant Vantage I, L.p. |
10% Owner |
– – • |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
662,444 |
662,444 |
|
- |
|
| Versant Vantage I, L.p. |
10% Owner |
– – • |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,429,895 |
2,429,895 |
|
- |
|
| Symons Julian A. |
See Remarks |
• – – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
18,517 |
394,064 |
|
- |
|
| Nuechterlein Carole |
Director |
– • – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
3,092,340 |
3,092,340 |
|
- |
|
| Blatt Lawrence |
Chief Executive Officer |
• – – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
273,058 |
18,517 |
|
- |
|
| Beigelman Leonid |
President |
• • – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
273,057 |
18,355 |
|
- |
|
32 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
